Beta Drugs opened at ₹1,845.00, in line with its previous close of ₹1,844.30. During today's session, the stock has traded between ₹1,660.00 and ₹1,859.40, with an average traded price of ₹1,712.68. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Beta Drugs is now worth
₹ 27,639.00
giving a profit of
₹ 17,639.00 (176.39%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-166.60 (-9.03%)
Day High
₹1,859.40
Day Low
₹1,660.00
Day Open
₹1,845.00
Prev Close
₹1,844.30
Volume
1,25,336
Value Traded
₹21.47 Cr
1W Return
-16.28%
1M Return
-20.81%
3M Return
-29.12%
6M Return
20.32%
1Y Return
-3.08%
Market Cap (₹ Cr.)
1,866
PE Ratio
44.20
PB Ratio
8.32
Dividend Yield
-
ROE
21.52%
ROCE
19.18%
Book Value (₹)
221.65
Face Value (₹)
10.00
EPS (TTM)
14.78
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-16.28%
6 Week
-
1 Month
-20.81%
3 Month
-29.12%
9 Month
4.42%
Beta Drugs gets Azerbaijan approval for oncology products, eyes FY27 sales
Beta Drugs received regulatory approval from Azerbaijan for its oncology products. The company aims to commence sales from this approval in FY27. The development expands Beta Drugs' international presence in the oncology segment.
21 days agoBeta Drugs Q1FY27 net profit rises 41% to ₹165 Mn on strong sales
Beta Drugs Ltd reported a 41% rise in Q1FY27 net profit to ₹165 Mn, driven by 25.2% revenue growth to ₹1,255 Mn. Branded oncology sales surged 47%, while EBITDA margins expanded to 21.83%. The company maintains its FY27 growth guidance of 20-25%.
2mo agoBeta Drugs completes Nivian Lifesciences acquisition
Beta Drugs Limited completed the acquisition of 66.09% equity shares in Nivian Lifesciences Private Limited, with the final transfer occurring on May 22, 2026. The company will now seek listing approval for the share swap arrangement. This move aligns with its Beta Vision 2030 strategy.
4mo agoBeta Drugs Achieves Regulatory Milestones in Azerbaijan and Philippines Markets
Beta Drugs Limited has secured important regulatory achievements in Azerbaijan and Philippines markets. The company's manufacturing facility successfully completed GMP inspection by Azerbaijan's Ministry of Health from April 13-17, 2026, with approval expected within 1-2 months. In Philippines, the company received product registration certificates for 2 brands representing first generic approvals in their categories, with additional approvals anticipated within 6 months to support expansion into Vietnam and Thailand markets.
5mo agoBeta Drugs Acquires 66% Stake in IVF Specialist Nivian Lifesciences for ₹69.4 Crore
Beta Drugs Ltd announced acquisition of 66.09% stake in IVF specialist Nivian Lifesciences for ₹69.4 crore, marking strategic entry into women's health segment. Stock surged 4% following announcement. Company reported H1 FY26 revenue growth of 13% to ₹203.6 crore, though net profit declined 2% to ₹23.9 crore.
9mo agoBeta Drugs to Acquire 66.09% Stake in Nivian Life Sciences for ₹694 Million
Beta Drugs announces acquisition of 66.09% controlling stake in Nivian Life Sciences for ₹694 million. This strategic investment provides Beta Drugs with majority control and enhances its presence in the pharmaceutical sector. The substantial acquisition demonstrates the company's commitment to growth through strategic partnerships and investments in life sciences.
9mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Beta Drugs is now worth
₹ 27,639.00
giving a profit of
₹ 17,639.00 (176.39%)
Note: Past profits do not guarantee future returns.
